Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer [Phase 1]
Phase 1 clinical-trial update exploring adding ZEN003694 (ZEN-3694) and pembrolizumab to nab-paclitaxel for patients with locally advanced o…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan [Phase 1]
Phase 1 trial evaluating the safety, adverse events, and pharmacokinetics of Azirkitug alone or in combination with Budigalimab, Bevacizumab…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer [Phase 1]
A Phase 1 trial is evaluating the addition of ASTX727 (cedazuridine/decitabine) to paclitaxel and pembrolizumab for metastatic or unresectab…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies [Phase 2]
A Phase 2 trial update from UNC Lineberger Comprehensive Cancer Center for biomarker-driven therapies in breast cancer, currently recruiting…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC
Clinical trial update on a study comparing chemotherapy versus immunotherapy as neoadjuvant therapy for triple-negative breast cancer, with …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer [NA]
This research trial outlines a nurse-led coping and supportive intervention for patients with triple-negative breast cancer and is not yet r…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors [Phase 1]
This clinical trial update reports a Phase 1 dose-determining study of EXS74539 (REC-4539) in participants with select solid tumors, current…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer [Phase 2]
Phase 2 platform study evaluating rechallenge with antibody-drug conjugates in ADC-treated metastatic breast cancer; recruitment is ongoing.
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating STEMVAC in combination with chemotherapy for PD-L1 negative metastatic triple-negative breast cancer, curr…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) [Phase 1, Phase 2]
Genmab is conducting a Phase 1/2 clinical trial of Rinatabart Sesutecan for multiple advanced solid tumors; recruitment is ongoing.
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC [Phase 1, Phase 2]
A Phase 1/2 trial is evaluating dual-target CAR-NK cell therapy for advanced breast cancer, including HER2-positive and triple-negative subt…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha [Phase 1]
Phase 1 study of MOv18 IgE in solid tumors expressing folate receptor alpha is currently recruiting, evaluating safety and early signals of …
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer [Phase 1]
Phase 1 trial PAveMenT is evaluating the combination of palbociclib and avelumab in metastatic AR-positive triple-negative breast cancer and…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. [Phase 1, Phase 2]
Cantargia's Nadunolimab is being studied in combination with gemcitabine and carboplatin for advanced triple-negative breast cancer in Phase…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) [Phase 2]
A Phase 2 trial evaluating a combination of alpelisib, an iNOS inhibitor, and nab-paclitaxel in HER2-negative metaplastic breast cancer, wit…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer [Phase 1]
This clinical trial update describes a Phase 1 study evaluating the combination CLBR001 and ABBV-461 for locally advanced or metastatic brea…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors [Phase 1]
Phase 1 clinical trial of ZM008, an anti-LLT1 antibody, given as a single agent and then in combination with toripalimab in patients with ad…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK [Phase 2]
A Phase 2 trial (INVINCIBLE-4-SAKK) testing intratumoral INT230-6 followed by neoadjuvant immuno-chemotherapy for early triple-negative brea…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer [Phase 3]
A Phase III randomized trial evaluating Dato-DXd in combination with Durvalumab for neoadjuvant/adjuvant treatment in triple-negative or hor…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) [Phase 1]
First-in-human, dose-escalation Phase 1 study of a dendritic cell vaccine (DCV) is underway, with recruitment for leptomeningeal carcinomato…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC [Phase 2]
Phase 2 clinical trial evaluating tumor-infiltrating lymphocyte–driven de-escalation of chemotherapy for Stage I-II triple-negative breast c…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) [Phase 2, Phase 3]
A Phase 2/3 clinical trial update comparing Izalontamab Brengitecan with standard chemotherapy in previously untreated, locally advanced, re…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy [EARLY_Phase 1]
A personalized dendritic cell vaccine is being evaluated in an early-phase trial for high-risk triple-negative breast cancer after neoadjuva…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating the combination of bicalutamide and abemaciclib for androgen receptor–positive triple-negative breast canc…
-
CLINICAL_TRIALS research · 2026-04-01Clinical Trial Update: Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer [Phase 2]
An update on a Phase 2 clinical trial evaluating Biolosion in combination with standard neoadjuvant therapy for triple-negative breast cance…